A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

S. Pusceddu, F. Barretta, A. Trama, L. Botta, M. Milione, R. Buzzoni, F. De Braud, V. Mazzaferro, U. Pastorino, E. Seregni, L. Mariani, G. Gatta, M. Di Bartolomeo, D. Femia, N. Prinzi, J. Coppa, F. Panzuto, L. Antonuzzo, E. Bajetta, M. Pia Brizzi & 46 others D. Campana, L. Catena, H. Comber, F. Dwane, N. Fazio, A. Faggiano, D. Giuffrida, K. Henau, T. Ibrahim, R. Marconcini, S. Massironi, M.P. Žakelj, F. Spada, S. Tafuto, E. Van Eycken, J.M. Van Der Zwan, T. Žagar, L. Giacomelli, R. Miceli, A. Francesca, B. Alberto, B. Rossana, B. Nicole, C. Sara, C. Carolina, C. Federica, C. Carlo, C. Francesca, D. Marilina, D.M. Vittoria, D.D. Chiara, E. Paola, L.S. Anna, L. Gabriele, L.R. Giuseppe, N. Federico, R. Alessandra, P. Vittorio, R. Paola, R. Maria, S. Sabine, T. Martina, V.D. Boukje, V. Otto, V. Claudio, NEPscore Working Group

Research output: Contribution to journalArticle

Abstract

No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS <70%; (III) poor risk group: 10-year OS
Original languageEnglish
Pages (from-to)607-618
Number of pages12
JournalEndocrine-Related Cancer
Volume25
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Neuroendocrine Tumors
Survival
Italy
Calibration
Databases
Neoplasm Metastasis

Keywords

  • Neuroendocrine tumors
  • Overall survival
  • Prognosis
  • Prognostic score
  • Validation
  • antineoplastic agent
  • Ki 67 antigen
  • peptide receptor radionuclide
  • unclassified drug
  • adult
  • aged
  • Article
  • cancer classification
  • cancer prognosis
  • cancer staging
  • cohort analysis
  • female
  • functional status
  • gastroenteropancreatic neuroendocrine tumor
  • human
  • lung cancer
  • major clinical study
  • male
  • medical record review
  • metastasis
  • middle aged
  • neuroendocrine tumor
  • overall survival
  • pancreas islet cell tumor
  • primary tumor
  • progression free survival
  • retrospective study

Cite this

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. / Pusceddu, S.; Barretta, F.; Trama, A.; Botta, L.; Milione, M.; Buzzoni, R.; De Braud, F.; Mazzaferro, V.; Pastorino, U.; Seregni, E.; Mariani, L.; Gatta, G.; Di Bartolomeo, M.; Femia, D.; Prinzi, N.; Coppa, J.; Panzuto, F.; Antonuzzo, L.; Bajetta, E.; Pia Brizzi, M.; Campana, D.; Catena, L.; Comber, H.; Dwane, F.; Fazio, N.; Faggiano, A.; Giuffrida, D.; Henau, K.; Ibrahim, T.; Marconcini, R.; Massironi, S.; Žakelj, M.P.; Spada, F.; Tafuto, S.; Van Eycken, E.; Van Der Zwan, J.M.; Žagar, T.; Giacomelli, L.; Miceli, R.; Francesca, A.; Alberto, B.; Rossana, B.; Nicole, B.; Sara, C.; Carolina, C.; Federica, C.; Carlo, C.; Francesca, C.; Marilina, D.; Vittoria, D.M.; Chiara, D.D.; Paola, E.; Anna, L.S.; Gabriele, L.; Giuseppe, L.R.; Federico, N.; Alessandra, R.; Vittorio, P.; Paola, R.; Maria, R.; Sabine, S.; Martina, T.; Boukje, V.D.; Otto, V.; Claudio, V.; Group, NEPscore Working.

In: Endocrine-Related Cancer, Vol. 25, No. 6, 2018, p. 607-618.

Research output: Contribution to journalArticle

Pusceddu, S, Barretta, F, Trama, A, Botta, L, Milione, M, Buzzoni, R, De Braud, F, Mazzaferro, V, Pastorino, U, Seregni, E, Mariani, L, Gatta, G, Di Bartolomeo, M, Femia, D, Prinzi, N, Coppa, J, Panzuto, F, Antonuzzo, L, Bajetta, E, Pia Brizzi, M, Campana, D, Catena, L, Comber, H, Dwane, F, Fazio, N, Faggiano, A, Giuffrida, D, Henau, K, Ibrahim, T, Marconcini, R, Massironi, S, Žakelj, MP, Spada, F, Tafuto, S, Van Eycken, E, Van Der Zwan, JM, Žagar, T, Giacomelli, L, Miceli, R, Francesca, A, Alberto, B, Rossana, B, Nicole, B, Sara, C, Carolina, C, Federica, C, Carlo, C, Francesca, C, Marilina, D, Vittoria, DM, Chiara, DD, Paola, E, Anna, LS, Gabriele, L, Giuseppe, LR, Federico, N, Alessandra, R, Vittorio, P, Paola, R, Maria, R, Sabine, S, Martina, T, Boukje, VD, Otto, V, Claudio, V & Group, NEPW 2018, 'A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors', Endocrine-Related Cancer, vol. 25, no. 6, pp. 607-618. https://doi.org/10.1530/ERC-17-0489
Pusceddu, S. ; Barretta, F. ; Trama, A. ; Botta, L. ; Milione, M. ; Buzzoni, R. ; De Braud, F. ; Mazzaferro, V. ; Pastorino, U. ; Seregni, E. ; Mariani, L. ; Gatta, G. ; Di Bartolomeo, M. ; Femia, D. ; Prinzi, N. ; Coppa, J. ; Panzuto, F. ; Antonuzzo, L. ; Bajetta, E. ; Pia Brizzi, M. ; Campana, D. ; Catena, L. ; Comber, H. ; Dwane, F. ; Fazio, N. ; Faggiano, A. ; Giuffrida, D. ; Henau, K. ; Ibrahim, T. ; Marconcini, R. ; Massironi, S. ; Žakelj, M.P. ; Spada, F. ; Tafuto, S. ; Van Eycken, E. ; Van Der Zwan, J.M. ; Žagar, T. ; Giacomelli, L. ; Miceli, R. ; Francesca, A. ; Alberto, B. ; Rossana, B. ; Nicole, B. ; Sara, C. ; Carolina, C. ; Federica, C. ; Carlo, C. ; Francesca, C. ; Marilina, D. ; Vittoria, D.M. ; Chiara, D.D. ; Paola, E. ; Anna, L.S. ; Gabriele, L. ; Giuseppe, L.R. ; Federico, N. ; Alessandra, R. ; Vittorio, P. ; Paola, R. ; Maria, R. ; Sabine, S. ; Martina, T. ; Boukje, V.D. ; Otto, V. ; Claudio, V. ; Group, NEPscore Working. / A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. In: Endocrine-Related Cancer. 2018 ; Vol. 25, No. 6. pp. 607-618.
@article{b1f3e1ea27d64152bf1f1e7da7e1dad8,
title = "A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors",
abstract = "No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70{\%}; (II) intermediate risk group: 30{\%} ≤ 10-year OS <70{\%}; (III) poor risk group: 10-year OS",
keywords = "Neuroendocrine tumors, Overall survival, Prognosis, Prognostic score, Validation, antineoplastic agent, Ki 67 antigen, peptide receptor radionuclide, unclassified drug, adult, aged, Article, cancer classification, cancer prognosis, cancer staging, cohort analysis, female, functional status, gastroenteropancreatic neuroendocrine tumor, human, lung cancer, major clinical study, male, medical record review, metastasis, middle aged, neuroendocrine tumor, overall survival, pancreas islet cell tumor, primary tumor, progression free survival, retrospective study",
author = "S. Pusceddu and F. Barretta and A. Trama and L. Botta and M. Milione and R. Buzzoni and {De Braud}, F. and V. Mazzaferro and U. Pastorino and E. Seregni and L. Mariani and G. Gatta and {Di Bartolomeo}, M. and D. Femia and N. Prinzi and J. Coppa and F. Panzuto and L. Antonuzzo and E. Bajetta and {Pia Brizzi}, M. and D. Campana and L. Catena and H. Comber and F. Dwane and N. Fazio and A. Faggiano and D. Giuffrida and K. Henau and T. Ibrahim and R. Marconcini and S. Massironi and M.P. Žakelj and F. Spada and S. Tafuto and {Van Eycken}, E. and {Van Der Zwan}, J.M. and T. Žagar and L. Giacomelli and R. Miceli and A. Francesca and B. Alberto and B. Rossana and B. Nicole and C. Sara and C. Carolina and C. Federica and C. Carlo and C. Francesca and D. Marilina and D.M. Vittoria and D.D. Chiara and E. Paola and L.S. Anna and L. Gabriele and L.R. Giuseppe and N. Federico and R. Alessandra and P. Vittorio and R. Paola and R. Maria and S. Sabine and T. Martina and V.D. Boukje and V. Otto and V. Claudio and Group, {NEPscore Working}",
note = "Export Date: 5 February 2019 CODEN: ERCAE Correspondence Address: Pusceddu, S.; Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Dei Tumori di MilanoItaly; email: sara.pusceddu@istitutotumori.mi.it Funding details: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Funding details: Fondazione IRCCS Policlinico San Matteo Funding text 1: The authors thank Ray Hill, an independent medical writer, who provided English language editing and journal styling prior to submission, on behalf of Springer Healthcare Communication. This assistance was funded by Novartis Farma, Italy. Members of the NEPscore working group: Aroldi Francesca (Fondazione Poliambulanza, Brescia, Italy), Bongiovanni Alberto (Centro di Osteoncologia e Tumori Rari, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy), Berardi Rossana (Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy), Brighi Nicole (Policlinico Sant’Orsola Malpighi, Bologna, Italy), Cingarlini Sara (Azienda Ospedaliera Universitaria, Verona, Italy), Cauchi Carolina (Ospedale S Croce e Carle, Cuneo, Italy), Cavalcoli Federica (Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Universit{\`a} degli Studi di Milano, Milan, Italy), Carnaghi Carlo (Istituto Clinico Humanitas, Rozzano, ENETS Center of Excellence, Italy), Corti Francesca (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Duro Marilina (Ospedale Valduce Como, Italy), Dav{\`i} Maria Vittoria (Ospedale Policlinico Borgo Roma, Verone, Italy), De Divitiis Chiara (IRCCS Fondazione Pascale, ENETS Center of Excellence, Naples, Italy), Ermacora Paola (Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, Italy), La Salvia Anna (Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy), Luppi Gabriele (Policlinico di Modena, Italy), Lo Russo Giuseppe (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Nichetti Federico (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Raimondi Alessandra (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Perfetti Vittorio (Fondazione IRCCS Policlinico San Matteo, SC oncologia, Pavia, Italy), Razzore Paola (Unit of Endocrinology, Ospedale Mauriziano, Torino, Italy), Rinzivillo Maria (Azienda Ospedaliera Universitaria Sant’Andrea, ENETS Center of Excellence, Rome, Italy), Siesling Sabine (Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands), Torchio Martina (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Van Dijk Boukje (Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research, Utrecht, The Netherlands), Visser Otto (Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands), Vernieri Claudio (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy). References: Akaike, H., Information theory and an extension of the maximum likelihood principle (1973) 2nd International Symposium on Information Theory, pp. 267-281. , Eds BN Petrov & F Csaki. Budapest, Hungary: Akad{\'e}miai Kiad; Bosman, F.P., Carneiro, F., Hruban, R.H., Theise, N.D., (2010) The World Health Organizazion Classification of the Digestive System, , Lyon, France: IARC Press; Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., Yao, J.C., Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States (2017) JAMA Oncology, 3, pp. 1335-1342. , https://doi.org/10.1001/jamaoncol.2017.0589; Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.L., Vinik, A., Lee, S.H., Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study (2017) Annals of Oncology, 28, pp. 339-343. , https://doi.org/10.1093/annonc/mdw561; Fraenkel, M., Kim, M.K., Faggiano, A., Valk, G.D., Epidemiology of gastroenteropancreatic neuroendocrine tumours (2012) Best Practice and Research: Clinical Gastroenterology, 26, pp. 691-703. , https://doi.org/10.1016/j.bpg.2013.01.006; Frilling, A., Modlin, I.M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Vilgrain, V., Recommendations for management of patients with neuroendocrine liver metastases (2014) Lancet Oncology, 15, pp. 8-21. , https://doi.org/10.1016/S1470-2045(13)70362-0; Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Siesling, S., Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet-a population-based study (2017) Lancet Oncology, 18, pp. 1022-1039. , https://doi.org/10.1016/S1470-2045(17)30445-X; Gen{\cc}, C.G., Jilesen, A.P., Partelli, S., Falconi, M., Muffatti, F., Van Kemenade, F.J., Van Eeden, S., Van Eijck, C.H.J., A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors (2017) Annals of Surgery [Epub], , https://doi.org/10.1097/SLA.0000000000002123; Harrell, F.E., Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors (1996) Statistics in Medicine, 15, pp. 361-387. , https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4361::AID-SIM1683.0.CO;2-4; Kulke, M.H., Lenz, H.J., Meropol, N.J., Posey, J., Ryan, D.P., Picus, J., Bergsland, E., Huang, X., Activity of sunitinib in patients with advanced neuroendocrine tumors (2008) Journal of Clinical Oncology, 26, pp. 3403-3410. , https://doi.org/10.1200/JCO.2007.15.9020; Lamarca, A., Walter, T., Pavel, M., Borbath, I., Freis, P., Nu{\~n}ez, B., Childs, A., Garcia-Carbonero, R., Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas (2017) Journal of the National Cancer Institute, 109, pp. 1-9; Mariani, L., Miceli, R., Kattan, M.W., Brennan, M.F., Colecchia, M., Fiore, M., Casali, P.G., Gronchi, A., Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system (2005) Cancer, 103, pp. 402-408. , https://doi.org/10.1002/cncr.20778; Modlin, I.M., Gustafsson, B.I., Pavel, M., Svejda, B., Lawrence, B., Kidd, M., A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival (2010) Neuroendocrinology, 92, pp. 143-157. , https://doi.org/10.1159/000319784; Motzer, R.J., Bukowski, R.M., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Kim, S.T., Baum, C.M., Kattan, M.W., Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (2008) Cancer, 113, pp. 1552-1558. , https://doi.org/10.1002/cncr.23776; {\"O}berg, K., Knigge, U., Kwekkeboom, D., Perren, A., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012) Annals of Oncology, 23, pp. 124-130. , https://doi.org/10.1093/annonc/mds295; Panzuto, F., Rinzivillo, M., Fazio, N., De Braud, F., Luppi, G., Zatelli, M.C., Lugli, F., Nuzzo, C., Real-world study of everolimus in advanced progressive neuroendocrine tumors (2014) Oncologist, 19, pp. 966-974. , https://doi.org/10.1634/theoncologist.2014-0037; Panzuto, F., Merola, E., Pavel, M.E., Rinke, A., Kump, P., Partelli, S., Rinzivillo, M., Lipp, R., Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: A risk score to predict clinical outcome (2017) Oncologist, 22, pp. 409-415. , https://doi.org/10.1634/theoncologist.2016-0351; Pavel, M.E., Hainsworth, J.D., Baudin, E., Peeters, M., H{\"o}rsch, D., Winkler, R.E., Klimovsky, J., Wolin, E.M., Everolimusplus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study (2011) Lancet, 378, pp. 2005-2012. , https://doi.org/10.1016/S0140-6736(11)61742-X; Pavel, M.E., Baudin, E., Oberg, K.E., Hainsworth, J.D., Voi, M., Rouyrre, N., Peeters, M., Yao, J.C., Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017) Annals of Oncology, 28, pp. 1569-1575. , https://doi.org/10.1093/annonc/mdx193; Pusceddu, S., Verzoni, E., Prinzi, N., Mennitto, A., Femia, D., Grassi, P., Concas, L., Procopio, G., Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential (2017) Therapeutic Advances in Medical Oncology, 9, pp. 183-188. , https://doi.org/10.1177/1758834016683905; Rindi, G., Arnold, R., Bosman, F., Cappella, C., Klimstra, D.S., Kloppel, G., Komminoth, P., Solcia, E., Nomenclature and classification of digestive neuroendocrine tumours (2010) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, pp. 10-12. , 1st ed., Eds SR Hamilton & LA Aaltonen. Lyon, France: IARC Press; Rinke, A., M{\"u}ller, H.H., Schade-Brittinger, C., Klose, K.J., Barth, P., Wied, M., Mayer, C., Bl{\"a}ker, M., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group (2009) Journal of Clinical Oncology, 27, pp. 4656-4663. , https://doi.org/10.1200/JCO.2009.22.8510; Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T.M., M{\"u}ller, H.H., Arnold, R., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival (2017) Neuroendocrinology, 104, pp. 26-32. , https://doi.org/10.1159/000443612; Scarpa, A., Chang, D.K., Nones, K., Corbo, V., Patch, A.M., Bailey, P., Lawlor, R.T., Mafficini, A., Whole-genome landscape of pancreatic neuroendocrine tumours (2017) Nature, 543, pp. 65-71. , https://doi.org/10.1038/nature21063; Strosberg, J.R., Weber, J.M., Choi, J., Campos, T.L., Valone, T.L., Han, G., Schell, M.J., Kvols, L.K., A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors (2012) Annals of Oncology, 23, pp. 2335-2341. , https://doi.org/10.1093/annonc/mdr614; Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Jacene, H., Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (2017) New England Journal of Medicine, 376, pp. 125-135. , https://doi.org/10.1056/NEJMoa1607427; Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., (2015) WHO Classification of Tumours of the Lung, Pleura, Tymus and Heart. World Health Organization Classification of Tumours, , Lyon, France: IARC Press; Van Der Zwan, J.M., Trama, A., Otter, R., Larra{\~n}aga, N., Tavilla, A., Marcos-Gragera, R., Dei Tos, A.P., Links, T., Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project (2013) European Journal of Cancer, 49, pp. 2565-2578. , https://doi.org/10.1016/j.ejca.2013.02.029; Yao, J.C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J.E., Abdalla, E.K., Rashid, A., One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States (2008) Journal of Clinical Oncology, 26, pp. 3063-3072. , https://doi.org/10.1200/JCO.2007.15.4377; Yao, J.C., Lombard-Bohas, C., Baudin, E., Kvols, L.K., Rougier, P., Ruszniewski, P., Hoosen, S., Lebwohl, D., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial (2010) Journal of Clinical Oncology, 28, pp. 69-76. , https://doi.org/10.1200/JCO.2009.24.2669; Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin, E.M., Van Cutsem, E., Hobday, T.J., De Vries, E.G., Everolimus for advanced pancreatic neuroendocrine tumors (2011) New England Journal of Medicine, 364, pp. 514-523. , https://doi.org/10.1056/NEJMoa1009290; Yao, J.C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Voi, M., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study (2016) Lancet, 387, pp. 968-977. , https://doi.org/10.1016/S0140-6736(15)00817-X; Yao, J.C., Pavel, M., Lombard-Bohas, C., Van Cutsem, E., Voi, M., Brandt, U., He, W., Tomassetti, P., Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study (2017) Journal of Clinical Oncology, 34, pp. 3906-3913. , https://doi.org/10.1200/JCO.2016.68.0702",
year = "2018",
doi = "10.1530/ERC-17-0489",
language = "English",
volume = "25",
pages = "607--618",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "6",

}

TY - JOUR

T1 - A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

AU - Pusceddu, S.

AU - Barretta, F.

AU - Trama, A.

AU - Botta, L.

AU - Milione, M.

AU - Buzzoni, R.

AU - De Braud, F.

AU - Mazzaferro, V.

AU - Pastorino, U.

AU - Seregni, E.

AU - Mariani, L.

AU - Gatta, G.

AU - Di Bartolomeo, M.

AU - Femia, D.

AU - Prinzi, N.

AU - Coppa, J.

AU - Panzuto, F.

AU - Antonuzzo, L.

AU - Bajetta, E.

AU - Pia Brizzi, M.

AU - Campana, D.

AU - Catena, L.

AU - Comber, H.

AU - Dwane, F.

AU - Fazio, N.

AU - Faggiano, A.

AU - Giuffrida, D.

AU - Henau, K.

AU - Ibrahim, T.

AU - Marconcini, R.

AU - Massironi, S.

AU - Žakelj, M.P.

AU - Spada, F.

AU - Tafuto, S.

AU - Van Eycken, E.

AU - Van Der Zwan, J.M.

AU - Žagar, T.

AU - Giacomelli, L.

AU - Miceli, R.

AU - Francesca, A.

AU - Alberto, B.

AU - Rossana, B.

AU - Nicole, B.

AU - Sara, C.

AU - Carolina, C.

AU - Federica, C.

AU - Carlo, C.

AU - Francesca, C.

AU - Marilina, D.

AU - Vittoria, D.M.

AU - Chiara, D.D.

AU - Paola, E.

AU - Anna, L.S.

AU - Gabriele, L.

AU - Giuseppe, L.R.

AU - Federico, N.

AU - Alessandra, R.

AU - Vittorio, P.

AU - Paola, R.

AU - Maria, R.

AU - Sabine, S.

AU - Martina, T.

AU - Boukje, V.D.

AU - Otto, V.

AU - Claudio, V.

AU - Group, NEPscore Working

N1 - Export Date: 5 February 2019 CODEN: ERCAE Correspondence Address: Pusceddu, S.; Department of Medical Oncology, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale Dei Tumori di MilanoItaly; email: sara.pusceddu@istitutotumori.mi.it Funding details: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Funding details: Fondazione IRCCS Policlinico San Matteo Funding text 1: The authors thank Ray Hill, an independent medical writer, who provided English language editing and journal styling prior to submission, on behalf of Springer Healthcare Communication. This assistance was funded by Novartis Farma, Italy. Members of the NEPscore working group: Aroldi Francesca (Fondazione Poliambulanza, Brescia, Italy), Bongiovanni Alberto (Centro di Osteoncologia e Tumori Rari, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy), Berardi Rossana (Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy), Brighi Nicole (Policlinico Sant’Orsola Malpighi, Bologna, Italy), Cingarlini Sara (Azienda Ospedaliera Universitaria, Verona, Italy), Cauchi Carolina (Ospedale S Croce e Carle, Cuneo, Italy), Cavalcoli Federica (Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy), Carnaghi Carlo (Istituto Clinico Humanitas, Rozzano, ENETS Center of Excellence, Italy), Corti Francesca (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Duro Marilina (Ospedale Valduce Como, Italy), Davì Maria Vittoria (Ospedale Policlinico Borgo Roma, Verone, Italy), De Divitiis Chiara (IRCCS Fondazione Pascale, ENETS Center of Excellence, Naples, Italy), Ermacora Paola (Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, Italy), La Salvia Anna (Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy), Luppi Gabriele (Policlinico di Modena, Italy), Lo Russo Giuseppe (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Nichetti Federico (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Raimondi Alessandra (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Perfetti Vittorio (Fondazione IRCCS Policlinico San Matteo, SC oncologia, Pavia, Italy), Razzore Paola (Unit of Endocrinology, Ospedale Mauriziano, Torino, Italy), Rinzivillo Maria (Azienda Ospedaliera Universitaria Sant’Andrea, ENETS Center of Excellence, Rome, Italy), Siesling Sabine (Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands), Torchio Martina (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy), Van Dijk Boukje (Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research, Utrecht, The Netherlands), Visser Otto (Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands), Vernieri Claudio (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, ENETS Center of Excellence, Milan, Italy). References: Akaike, H., Information theory and an extension of the maximum likelihood principle (1973) 2nd International Symposium on Information Theory, pp. 267-281. , Eds BN Petrov & F Csaki. Budapest, Hungary: Akadémiai Kiad; Bosman, F.P., Carneiro, F., Hruban, R.H., Theise, N.D., (2010) The World Health Organizazion Classification of the Digestive System, , Lyon, France: IARC Press; Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., Yao, J.C., Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States (2017) JAMA Oncology, 3, pp. 1335-1342. , https://doi.org/10.1001/jamaoncol.2017.0589; Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.L., Vinik, A., Lee, S.H., Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study (2017) Annals of Oncology, 28, pp. 339-343. , https://doi.org/10.1093/annonc/mdw561; Fraenkel, M., Kim, M.K., Faggiano, A., Valk, G.D., Epidemiology of gastroenteropancreatic neuroendocrine tumours (2012) Best Practice and Research: Clinical Gastroenterology, 26, pp. 691-703. , https://doi.org/10.1016/j.bpg.2013.01.006; Frilling, A., Modlin, I.M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Vilgrain, V., Recommendations for management of patients with neuroendocrine liver metastases (2014) Lancet Oncology, 15, pp. 8-21. , https://doi.org/10.1016/S1470-2045(13)70362-0; Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Siesling, S., Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet-a population-based study (2017) Lancet Oncology, 18, pp. 1022-1039. , https://doi.org/10.1016/S1470-2045(17)30445-X; Genç, C.G., Jilesen, A.P., Partelli, S., Falconi, M., Muffatti, F., Van Kemenade, F.J., Van Eeden, S., Van Eijck, C.H.J., A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors (2017) Annals of Surgery [Epub], , https://doi.org/10.1097/SLA.0000000000002123; Harrell, F.E., Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors (1996) Statistics in Medicine, 15, pp. 361-387. , https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4361::AID-SIM1683.0.CO;2-4; Kulke, M.H., Lenz, H.J., Meropol, N.J., Posey, J., Ryan, D.P., Picus, J., Bergsland, E., Huang, X., Activity of sunitinib in patients with advanced neuroendocrine tumors (2008) Journal of Clinical Oncology, 26, pp. 3403-3410. , https://doi.org/10.1200/JCO.2007.15.9020; Lamarca, A., Walter, T., Pavel, M., Borbath, I., Freis, P., Nuñez, B., Childs, A., Garcia-Carbonero, R., Design and validation of the GI-NEC score to prognosticate overall survival in patients with high-grade gastrointestinal neuroendocrine carcinomas (2017) Journal of the National Cancer Institute, 109, pp. 1-9; Mariani, L., Miceli, R., Kattan, M.W., Brennan, M.F., Colecchia, M., Fiore, M., Casali, P.G., Gronchi, A., Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system (2005) Cancer, 103, pp. 402-408. , https://doi.org/10.1002/cncr.20778; Modlin, I.M., Gustafsson, B.I., Pavel, M., Svejda, B., Lawrence, B., Kidd, M., A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival (2010) Neuroendocrinology, 92, pp. 143-157. , https://doi.org/10.1159/000319784; Motzer, R.J., Bukowski, R.M., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Kim, S.T., Baum, C.M., Kattan, M.W., Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (2008) Cancer, 113, pp. 1552-1558. , https://doi.org/10.1002/cncr.23776; Öberg, K., Knigge, U., Kwekkeboom, D., Perren, A., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012) Annals of Oncology, 23, pp. 124-130. , https://doi.org/10.1093/annonc/mds295; Panzuto, F., Rinzivillo, M., Fazio, N., De Braud, F., Luppi, G., Zatelli, M.C., Lugli, F., Nuzzo, C., Real-world study of everolimus in advanced progressive neuroendocrine tumors (2014) Oncologist, 19, pp. 966-974. , https://doi.org/10.1634/theoncologist.2014-0037; Panzuto, F., Merola, E., Pavel, M.E., Rinke, A., Kump, P., Partelli, S., Rinzivillo, M., Lipp, R., Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: A risk score to predict clinical outcome (2017) Oncologist, 22, pp. 409-415. , https://doi.org/10.1634/theoncologist.2016-0351; Pavel, M.E., Hainsworth, J.D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R.E., Klimovsky, J., Wolin, E.M., Everolimusplus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study (2011) Lancet, 378, pp. 2005-2012. , https://doi.org/10.1016/S0140-6736(11)61742-X; Pavel, M.E., Baudin, E., Oberg, K.E., Hainsworth, J.D., Voi, M., Rouyrre, N., Peeters, M., Yao, J.C., Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017) Annals of Oncology, 28, pp. 1569-1575. , https://doi.org/10.1093/annonc/mdx193; Pusceddu, S., Verzoni, E., Prinzi, N., Mennitto, A., Femia, D., Grassi, P., Concas, L., Procopio, G., Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential (2017) Therapeutic Advances in Medical Oncology, 9, pp. 183-188. , https://doi.org/10.1177/1758834016683905; Rindi, G., Arnold, R., Bosman, F., Cappella, C., Klimstra, D.S., Kloppel, G., Komminoth, P., Solcia, E., Nomenclature and classification of digestive neuroendocrine tumours (2010) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, pp. 10-12. , 1st ed., Eds SR Hamilton & LA Aaltonen. Lyon, France: IARC Press; Rinke, A., Müller, H.H., Schade-Brittinger, C., Klose, K.J., Barth, P., Wied, M., Mayer, C., Bläker, M., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group (2009) Journal of Clinical Oncology, 27, pp. 4656-4663. , https://doi.org/10.1200/JCO.2009.22.8510; Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T.M., Müller, H.H., Arnold, R., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival (2017) Neuroendocrinology, 104, pp. 26-32. , https://doi.org/10.1159/000443612; Scarpa, A., Chang, D.K., Nones, K., Corbo, V., Patch, A.M., Bailey, P., Lawlor, R.T., Mafficini, A., Whole-genome landscape of pancreatic neuroendocrine tumours (2017) Nature, 543, pp. 65-71. , https://doi.org/10.1038/nature21063; Strosberg, J.R., Weber, J.M., Choi, J., Campos, T.L., Valone, T.L., Han, G., Schell, M.J., Kvols, L.K., A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors (2012) Annals of Oncology, 23, pp. 2335-2341. , https://doi.org/10.1093/annonc/mdr614; Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Jacene, H., Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (2017) New England Journal of Medicine, 376, pp. 125-135. , https://doi.org/10.1056/NEJMoa1607427; Travis, W.D., Brambilla, E., Burke, A.P., Marx, A., Nicholson, A.G., (2015) WHO Classification of Tumours of the Lung, Pleura, Tymus and Heart. World Health Organization Classification of Tumours, , Lyon, France: IARC Press; Van Der Zwan, J.M., Trama, A., Otter, R., Larrañaga, N., Tavilla, A., Marcos-Gragera, R., Dei Tos, A.P., Links, T., Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project (2013) European Journal of Cancer, 49, pp. 2565-2578. , https://doi.org/10.1016/j.ejca.2013.02.029; Yao, J.C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J.E., Abdalla, E.K., Rashid, A., One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States (2008) Journal of Clinical Oncology, 26, pp. 3063-3072. , https://doi.org/10.1200/JCO.2007.15.4377; Yao, J.C., Lombard-Bohas, C., Baudin, E., Kvols, L.K., Rougier, P., Ruszniewski, P., Hoosen, S., Lebwohl, D., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial (2010) Journal of Clinical Oncology, 28, pp. 69-76. , https://doi.org/10.1200/JCO.2009.24.2669; Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin, E.M., Van Cutsem, E., Hobday, T.J., De Vries, E.G., Everolimus for advanced pancreatic neuroendocrine tumors (2011) New England Journal of Medicine, 364, pp. 514-523. , https://doi.org/10.1056/NEJMoa1009290; Yao, J.C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Voi, M., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study (2016) Lancet, 387, pp. 968-977. , https://doi.org/10.1016/S0140-6736(15)00817-X; Yao, J.C., Pavel, M., Lombard-Bohas, C., Van Cutsem, E., Voi, M., Brandt, U., He, W., Tomassetti, P., Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study (2017) Journal of Clinical Oncology, 34, pp. 3906-3913. , https://doi.org/10.1200/JCO.2016.68.0702

PY - 2018

Y1 - 2018

N2 - No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS <70%; (III) poor risk group: 10-year OS

AB - No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS <70%; (III) poor risk group: 10-year OS

KW - Neuroendocrine tumors

KW - Overall survival

KW - Prognosis

KW - Prognostic score

KW - Validation

KW - antineoplastic agent

KW - Ki 67 antigen

KW - peptide receptor radionuclide

KW - unclassified drug

KW - adult

KW - aged

KW - Article

KW - cancer classification

KW - cancer prognosis

KW - cancer staging

KW - cohort analysis

KW - female

KW - functional status

KW - gastroenteropancreatic neuroendocrine tumor

KW - human

KW - lung cancer

KW - major clinical study

KW - male

KW - medical record review

KW - metastasis

KW - middle aged

KW - neuroendocrine tumor

KW - overall survival

KW - pancreas islet cell tumor

KW - primary tumor

KW - progression free survival

KW - retrospective study

U2 - 10.1530/ERC-17-0489

DO - 10.1530/ERC-17-0489

M3 - Article

VL - 25

SP - 607

EP - 618

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 6

ER -